{"frequencyBands":{"HP:0040280":[100,100],"HP:0040281":[80,99],"HP:0040282":[30,79],"HP:0040283":[5,29],"HP:0040284":[1,4],"HP:0040285":[0,0]},"page":{"anchorSlug":"atypical-hemolytic-uremic","columns":[{"gene":"","key":"population-96df18172986a0e0adbd","label":"Atypical hemolytic uremic syndrome","mondoId":"MONDO:0016244","onsetQualifier":null,"originColumnKey":"MONDO:0016244/ORPHA:2134","originalViews":[{"key":"MONDO:0016244/ORPHA:2134","label":"Atypical hemolytic uremic syndrome","scopeLabel":"ORPHA:2134","sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."}],"recordKeys":["055a8a2b422c7b92eff097ab5a3852f5044347601f0309f3f34f22134ba4000d","29abcf1e757f18753db29ee66309298e3844ea9491a0e1764e74ea3b178bd3ef","2d8e3712f017eab6bf2ad4f45846941d626cd0d131f42f36551075eb2c75efe2","339c3379786972b3a375a298fdcf09955dc0e5d43af74a66305b0ba84a2e32d9","43f9681aabb458999635f2ce0b154f303b1c6e83cb3f14dee561dbeca47c05db","5505b755f2a44bb1a691bdda885ba2f8eb9dcb01e86dddc518228baf989a20ea","69de9a3cf9cb89faf082c5d11e86ddd83667c876c756b6ddf133edb19d3c4bb2","8ae43005b2e2464215cdcf62e4842d54f3f2b190a5ab5725f700467e19da6daf","9f2090865f0dee2e422286430ebfcd131c9eb2b0821daccbfb842add2d8d1889","cce79f8227510a9062ca906a8327187751d4f6c67370b5df6aba2b9889023805","d21ef5a33eeaa3ae6200224997f15efb14eea64674830c600ca56e0dfd546b04","dce81326a9b3f399e9a0973840418f7b15fc64c70eb4115cf0eb60e99ba5f73e","e558e45096dc3c1dfad94e4d689acad783cfe5e91c813bcd863c6d9ef21da5ed"],"recordQualifiers":{},"scopeLabel":"ORPHA:2134","sourceIds":["ORPHA:2134"],"sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."}],"comparison":{"collapseColumnsLabel":"Show default populations","defaultColumnKeys":["population-96df18172986a0e0adbd"],"expandColumnsLabel":"Show all source populations","intro":"Features recorded for this MONDO node. Related-node evidence is available through separately scoped comparisons.","primaryFeatureIds":["HP:0045040","HP:0001871","HP:0005339","HP:0001939","HP:0001919","HP:0005416","HP:0005356"],"scopeNoteHtml":"<p>Each column retains its native condition identifier, assessed population and annotation references. Counts are not pooled.</p>"},"coverage":{"countRecords":0,"emptyColumnKeys":[],"hpoRelease":"2026-06-23","narrativeSourceChanges":[],"records":13,"sourceGroups":{"orphanet":13}},"features":[{"hpoId":"HP:0045040","label":"Abnormal circulating lactate dehydrogenase concentration","primary":true},{"hpoId":"HP:0001871","label":"Abnormality of blood and blood-forming tissues","primary":true},{"hpoId":"HP:0005339","label":"Abnormality of complement system","primary":true},{"hpoId":"HP:0001939","label":"Abnormality of metabolism/homeostasis","primary":true},{"hpoId":"HP:0001919","label":"Acute kidney injury","primary":true},{"hpoId":"HP:0005416","label":"Decreased circulating complement factor B concentration","primary":true},{"hpoId":"HP:0005356","label":"Decreased circulating complement factor I concentration","primary":true},{"hpoId":"HP:0040229","label":"Decreased level of thrombomodulin","primary":false},{"hpoId":"HP:0000790","label":"Hematuria","primary":false},{"hpoId":"HP:0001937","label":"Microangiopathic hemolytic anemia","primary":false},{"hpoId":"HP:0000093","label":"Proteinuria","primary":false},{"hpoId":"HP:0004431","label":"Reduced circulating complement concentration","primary":false},{"hpoId":"HP:0001873","label":"Thrombocytopenia","primary":false}],"ledeHtml":"Atypical hemolytic-uremic syndrome is a disease that primarily affects kidney function. This condition, which can occur at any age, causes abnormal blood clots (thrombi) to form in small blood vessels in the kidneys. These clots can cause serious medical problems if they restrict or block blood flow. Atypical hemolytic-uremic syndrome is characterized by three major features related to abnormal clotting: hemolytic anemia, thrombocytopenia, and kidney failure.","mondoId":"MONDO:0016244","node":{"canonicalSlug":"atypical-hemolytic-uremic","comparisons":[{"documentSha256":"cc390067dd38b2e6283c3a2d40fc295290ada6943d5a5e1fdb5459cc0f785fd6","key":"legacy-atypical-hemolytic-uremic","kind":"legacy","label":"atypical hemolytic-uremic syndrome","memberIds":["MONDO:0013040","MONDO:0013041","MONDO:0013042","MONDO:0013043","MONDO:0013044","MONDO:0016244"],"mondoId":"MONDO:0016244","url":"https://kcjyutqgtpgteszueluf.supabase.co/storage/v1/object/public/community-guides/learn-data/atypical-hemolytic-uremic.cc390067dd38b2e6283c3a2d40fc295290ada6943d5a5e1fdb5459cc0f785fd6.json"}],"contexts":[],"lifecycle":"active","narrative":{"causes":["Atypical hemolytic-uremic syndrome often results from a combination of environmental and genetic factors. Mutations in at least seven genes appear to increase the risk of developing the disorder. Mutations in a gene called CFH are most common; they have been found in about 30 percent of all cases of atypical hemolytic-uremic syndrome. Mutations in the other genes have each been identified in a smaller percentage of cases.","The genes associated with atypical hemolytic-uremic syndrome provide instructions for making proteins involved in a part of the body's immune response known as the complement system. This system is a group of proteins that work together to destroy foreign invaders (such as bacteria and viruses), trigger inflammation, and remove debris from cells and tissues. The complement system must be carefully regulated so it targets only unwanted materials and does not attack the body's healthy cells. The regulatory proteins associated with atypical hemolytic-uremic syndrome protect healthy cells by preventing activation of the complement system when it is not needed.","Mutations in the genes associated with atypical hemolytic-uremic syndrome lead to uncontrolled activation of the complement system. The overactive system attacks cells that line blood vessels in the kidneys, causing inflammation and the formation of abnormal clots. These abnormalities lead to kidney damage and, in many cases, kidney failure and ESRD.","Although gene mutations increase the risk of atypical hemolytic-uremic syndrome, studies suggest that they are often not sufficient to cause the disease. In people with certain genetic changes, the signs and symptoms of the disorder may be triggered by factors including certain medications (such as anticancer drugs), chronic diseases, viral or bacterial infections, cancers, organ transplantation, or pregnancy.","Some people with atypical hemolytic-uremic syndrome do not have any known genetic changes or environmental triggers for the disease. In these cases, the disorder is described as idiopathic."],"causesUrl":"https://medlineplus.gov/genetics/condition/atypical-hemolytic-uremic-syndrome/#causes","contentForm":"summary","matchMethod":"automatic-preferred-name","name":"Atypical hemolytic-uremic syndrome","paragraphs":["Atypical hemolytic-uremic syndrome is a disease that primarily affects kidney function. This condition, which can occur at any age, causes abnormal blood clots (thrombi) to form in small blood vessels in the kidneys. These clots can cause serious medical problems if they restrict or block blood flow. Atypical hemolytic-uremic syndrome is characterized by three major features related to abnormal clotting: hemolytic anemia, thrombocytopenia, and kidney failure.","Hemolytic anemia occurs when red blood cells break down (undergo hemolysis) prematurely. In atypical hemolytic-uremic syndrome, red blood cells can break apart as they squeeze past clots within small blood vessels. Anemia results if these cells are destroyed faster than the body can replace them. Anemia can lead to unusually pale skin (pallor), yellowing of the eyes and skin (jaundice), fatigue, shortness of breath, and a rapid heart rate.","Thrombocytopenia is a reduced level of circulating platelets, which are cells that normally assist with blood clotting. In people with atypical hemolytic-uremic syndrome, fewer platelets are available in the bloodstream because a large number of platelets are used to make abnormal clots. Thrombocytopenia can cause easy bruising and abnormal bleeding.","As a result of clot formation in small blood vessels, people with atypical hemolytic-uremic syndrome experience kidney damage and acute kidney failure that lead to end-stage renal disease (ESRD) in about half of all cases. These life-threatening complications prevent the kidneys from filtering fluids and waste products from the body effectively.","Atypical hemolytic-uremic syndrome should be distinguished from a more common condition called typical hemolytic-uremic syndrome. The two disorders have different causes and different signs and symptoms. Unlike the atypical form, the typical form is caused by infection with certain strains of Escherichia coli bacteria that produce toxic substances called Shiga-like toxins. The typical form is characterized by severe diarrhea and most often affects children younger than 10. The typical form is less likely than the atypical form to involve recurrent attacks of kidney damage that lead to ESRD."],"reviewed":"2010-06","scope":"exact","scopeNote":"","source":"MedlinePlus","sourceRelease":"2026-10-01","upstream":"MedlinePlus Genetics","url":"https://medlineplus.gov/genetics/condition/atypical-hemolytic-uremic-syndrome"},"ownColumnKeys":["population-96df18172986a0e0adbd"],"publication":"published","relationships":[{"kind":"parent","label":"syndromic disease","mondoId":"MONDO:0002254","slug":null},{"kind":"parent","label":"complement deficiency","mondoId":"MONDO:0003832","slug":null},{"kind":"parent","label":"thrombotic microangiopathy","mondoId":"MONDO:0019737","slug":"thrombotic-microangiopathy"},{"kind":"parent","label":"hereditary hemolytic uremic syndrome","mondoId":"MONDO:0957097","slug":null},{"kind":"child","label":"atypical hemolytic-uremic syndrome with DGKE deficiency","mondoId":"MONDO:0018159","slug":null},{"kind":"child","label":"atypical hemolytic-uremic syndrome with anti-factor H antibodies","mondoId":"MONDO:0019739","slug":null},{"kind":"child","label":"atypical hemolytic uremic syndrome with complement gene abnormality","mondoId":"MONDO:0035290","slug":null}],"schemaVersion":1,"searchIndex":"/node-search/manifest.json","sourceHolds":{},"summaryHolds":[],"translation":"pending","articles":[{"articleId":"rarediseases.info.nih.gov/diseases/8702","pageMondoId":"MONDO:0016244","source":"GARD","name":"Atypical hemolytic-uremic syndrome","url":"https://rarediseases.info.nih.gov/diseases/8702","relationToPage":"same-condition","coveredMondoIds":["MONDO:0016244"],"status":"validated-exact-source","presentation":"additional-reference","evidence":["existing-offline-scope-validator","automatic-identity-and-attribution"],"reviewed":null,"sourceRelease":"2026-10-21T15:52:08Z","upstream":"GARD:0008702","rawAttribution":"MONDO:0016244","independentCorroborationEstablished":false}]},"records":[{"frequencyKind":"range","key":"055a8a2b422c7b92eff097ab5a3852f5044347601f0309f3f34f22134ba4000d","raw":{"aspect":"P","body_system":"metabolic","disease_id":"ORPHA:2134","disease_name":"Atypical hemolytic uremic syndrome","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0000093","is_excluded":false,"label":"Proteinuria","onset_id":null,"reference":"ORPHA:2134","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"29abcf1e757f18753db29ee66309298e3844ea9491a0e1764e74ea3b178bd3ef","raw":{"aspect":"P","body_system":"metabolic","disease_id":"ORPHA:2134","disease_name":"Atypical hemolytic uremic syndrome","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0000790","is_excluded":false,"label":"Hematuria","onset_id":null,"reference":"ORPHA:2134","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"2d8e3712f017eab6bf2ad4f45846941d626cd0d131f42f36551075eb2c75efe2","raw":{"aspect":"P","body_system":"genitourinary","disease_id":"ORPHA:2134","disease_name":"Atypical hemolytic uremic syndrome","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0001919","is_excluded":false,"label":"Acute kidney injury","onset_id":null,"reference":"ORPHA:2134","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"339c3379786972b3a375a298fdcf09955dc0e5d43af74a66305b0ba84a2e32d9","raw":{"aspect":"P","body_system":"blood","disease_id":"ORPHA:2134","disease_name":"Atypical hemolytic uremic syndrome","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0001937","is_excluded":false,"label":"Microangiopathic hemolytic anemia","onset_id":null,"reference":"ORPHA:2134","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"43f9681aabb458999635f2ce0b154f303b1c6e83cb3f14dee561dbeca47c05db","raw":{"aspect":"P","body_system":"immune","disease_id":"ORPHA:2134","disease_name":"Atypical hemolytic uremic syndrome","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0005339","is_excluded":false,"label":"Abnormality of complement system","onset_id":null,"reference":"ORPHA:2134","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"5505b755f2a44bb1a691bdda885ba2f8eb9dcb01e86dddc518228baf989a20ea","raw":{"aspect":"P","body_system":"immune","disease_id":"ORPHA:2134","disease_name":"Atypical hemolytic uremic syndrome","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0004431","is_excluded":false,"label":"Reduced circulating complement concentration","onset_id":null,"reference":"ORPHA:2134","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"69de9a3cf9cb89faf082c5d11e86ddd83667c876c756b6ddf133edb19d3c4bb2","raw":{"aspect":"P","body_system":"immune","disease_id":"ORPHA:2134","disease_name":"Atypical hemolytic uremic syndrome","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0005356","is_excluded":false,"label":"Decreased circulating complement factor I concentration","onset_id":null,"reference":"ORPHA:2134","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"8ae43005b2e2464215cdcf62e4842d54f3f2b190a5ab5725f700467e19da6daf","raw":{"aspect":"P","body_system":"metabolic","disease_id":"ORPHA:2134","disease_name":"Atypical hemolytic uremic syndrome","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0001939","is_excluded":false,"label":"Abnormality of metabolism/homeostasis","onset_id":null,"reference":"ORPHA:2134","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"9f2090865f0dee2e422286430ebfcd131c9eb2b0821daccbfb842add2d8d1889","raw":{"aspect":"P","body_system":"immune","disease_id":"ORPHA:2134","disease_name":"Atypical hemolytic uremic syndrome","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0005416","is_excluded":false,"label":"Decreased circulating complement factor B concentration","onset_id":null,"reference":"ORPHA:2134","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"cce79f8227510a9062ca906a8327187751d4f6c67370b5df6aba2b9889023805","raw":{"aspect":"P","body_system":"blood","disease_id":"ORPHA:2134","disease_name":"Atypical hemolytic uremic syndrome","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0001873","is_excluded":false,"label":"Thrombocytopenia","onset_id":null,"reference":"ORPHA:2134","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"d21ef5a33eeaa3ae6200224997f15efb14eea64674830c600ca56e0dfd546b04","raw":{"aspect":"P","body_system":"blood","disease_id":"ORPHA:2134","disease_name":"Atypical hemolytic uremic syndrome","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0040229","is_excluded":false,"label":"Decreased level of thrombomodulin","onset_id":null,"reference":"ORPHA:2134","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"dce81326a9b3f399e9a0973840418f7b15fc64c70eb4115cf0eb60e99ba5f73e","raw":{"aspect":"P","body_system":"blood","disease_id":"ORPHA:2134","disease_name":"Atypical hemolytic uremic syndrome","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0001871","is_excluded":false,"label":"Abnormality of blood and blood-forming tissues","onset_id":null,"reference":"ORPHA:2134","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"e558e45096dc3c1dfad94e4d689acad783cfe5e91c813bcd863c6d9ef21da5ed","raw":{"aspect":"P","body_system":"metabolic","disease_id":"ORPHA:2134","disease_name":"Atypical hemolytic uremic syndrome","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0045040","is_excluded":false,"label":"Abnormal circulating lactate dehydrogenase concentration","onset_id":null,"reference":"ORPHA:2134","source_release":"2026-06-23"},"sourceGroups":["orphanet"]}],"referenceLabels":{},"references":{"causeHtml":"<p class=\"section-source\">Source: <a href=\"https://medlineplus.gov/genetics/condition/atypical-hemolytic-uremic-syndrome\" rel=\"noreferrer\">MedlinePlus</a></p><p class=\"section-source\">Source: <a href=\"https://rarediseases.info.nih.gov/diseases/8702\" rel=\"noreferrer\">GARD</a></p><p class=\"section-source\">Source: <a href=\"https://monarchinitiative.org/MONDO:0016244\" rel=\"noreferrer\">MONDO</a></p><details class=\"deep-dive\"><summary>Narrative source and scope</summary><dl><dt>Content</dt><dd>summary</dd><dt>Scope</dt><dd>exact</dd><dt>Match method</dt><dd>automatic-preferred-name</dd><dt>Upstream attribution</dt><dd>MedlinePlus Genetics</dd></dl></details>","identityNote":"MONDO identifies this node. Native source populations, annotation references and qualified comparison views retain their original scopes.","importantHtml":""},"sections":[{"bodyHtml":"<p>Atypical hemolytic-uremic syndrome is a disease that primarily affects kidney function. This condition, which can occur at any age, causes abnormal blood clots (thrombi) to form in small blood vessels in the kidneys. These clots can cause serious medical problems if they restrict or block blood flow. Atypical hemolytic-uremic syndrome is characterized by three major features related to abnormal clotting: hemolytic anemia, thrombocytopenia, and kidney failure.</p><p>Hemolytic anemia occurs when red blood cells break down (undergo hemolysis) prematurely. In atypical hemolytic-uremic syndrome, red blood cells can break apart as they squeeze past clots within small blood vessels. Anemia results if these cells are destroyed faster than the body can replace them. Anemia can lead to unusually pale skin (pallor), yellowing of the eyes and skin (jaundice), fatigue, shortness of breath, and a rapid heart rate.</p><p>Thrombocytopenia is a reduced level of circulating platelets, which are cells that normally assist with blood clotting. In people with atypical hemolytic-uremic syndrome, fewer platelets are available in the bloodstream because a large number of platelets are used to make abnormal clots. Thrombocytopenia can cause easy bruising and abnormal bleeding.</p><p>As a result of clot formation in small blood vessels, people with atypical hemolytic-uremic syndrome experience kidney damage and acute kidney failure that lead to end-stage renal disease (ESRD) in about half of all cases. These life-threatening complications prevent the kidneys from filtering fluids and waste products from the body effectively.</p><p>Atypical hemolytic-uremic syndrome should be distinguished from a more common condition called typical hemolytic-uremic syndrome. The two disorders have different causes and different signs and symptoms. Unlike the atypical form, the typical form is caused by infection with certain strains of Escherichia coli bacteria that produce toxic substances called Shiga-like toxins. The typical form is characterized by severe diarrhea and most often affects children younger than 10. The typical form is less likely than the atypical form to involve recurrent attacks of kidney damage that lead to ESRD.</p><p class=\"section-source\">Source: <a href=\"https://medlineplus.gov/genetics/condition/atypical-hemolytic-uremic-syndrome\" rel=\"noreferrer\">MedlinePlus</a></p>","key":"overview","title":"Overview"},{"bodyHtml":"<p>Atypical hemolytic-uremic syndrome often results from a combination of environmental and genetic factors. Mutations in at least seven genes appear to increase the risk of developing the disorder. Mutations in a gene called CFH are most common; they have been found in about 30 percent of all cases of atypical hemolytic-uremic syndrome. Mutations in the other genes have each been identified in a smaller percentage of cases.</p><p>The genes associated with atypical hemolytic-uremic syndrome provide instructions for making proteins involved in a part of the body&#x27;s immune response known as the complement system. This system is a group of proteins that work together to destroy foreign invaders (such as bacteria and viruses), trigger inflammation, and remove debris from cells and tissues. The complement system must be carefully regulated so it targets only unwanted materials and does not attack the body&#x27;s healthy cells. The regulatory proteins associated with atypical hemolytic-uremic syndrome protect healthy cells by preventing activation of the complement system when it is not needed.</p><p>Mutations in the genes associated with atypical hemolytic-uremic syndrome lead to uncontrolled activation of the complement system. The overactive system attacks cells that line blood vessels in the kidneys, causing inflammation and the formation of abnormal clots. These abnormalities lead to kidney damage and, in many cases, kidney failure and ESRD.</p><p>Although gene mutations increase the risk of atypical hemolytic-uremic syndrome, studies suggest that they are often not sufficient to cause the disease. In people with certain genetic changes, the signs and symptoms of the disorder may be triggered by factors including certain medications (such as anticancer drugs), chronic diseases, viral or bacterial infections, cancers, organ transplantation, or pregnancy.</p><p>Some people with atypical hemolytic-uremic syndrome do not have any known genetic changes or environmental triggers for the disease. In these cases, the disorder is described as idiopathic.</p><p class=\"section-source\">Source: <a href=\"https://medlineplus.gov/genetics/condition/atypical-hemolytic-uremic-syndrome/#causes\" rel=\"noreferrer\">MedlinePlus</a></p>","key":"causes","title":"Causes"}],"sharedSources":[],"slug":"atypical-hemolytic-uremic","sourceDocuments":[{"name":"MedlinePlus: Atypical hemolytic-uremic syndrome","reviewed":"2010-06","source_release":"2026-10-01","url":"https://medlineplus.gov/genetics/condition/atypical-hemolytic-uremic-syndrome"},{"name":"GARD: Atypical hemolytic-uremic syndrome","reviewed":null,"source_release":"2026-10-21T15:52:08Z","url":"https://rarediseases.info.nih.gov/diseases/8702"},{"name":"MONDO: atypical hemolytic-uremic syndrome","reviewed":null,"source_release":"releases/2026-10-06","url":"https://monarchinitiative.org/MONDO:0016244"}],"sourceNote":"","synonyms":["aHUS","Atypical Hemolytic Uremic Syndrome","atypical hemolytic uremic syndrome","atypical HUS","D-HUS","D-minus hemolytic uremic syndrome (D-HUS)","hemolytic-uremic syndrome without diarrhea","hemolytic-uremic syndrome without diarrhoea","HUS, atypical","non-diarrhea-associated hemolytic uremic syndrome"],"takeawayHtml":"","title":"atypical hemolytic-uremic syndrome"},"schemaVersion":1}
